Online citations, reference lists, and bibliographies.
← Back to Search

Survival Of Pleural Malignant Mesothelioma In Italy: A Population‐based Study

F. Montanaro, R. Rosato, Manuela Gangemi, S. Roberti, F. Ricceri, E. Merler, V. Gennaro, A. Romanelli, E. Chellini, C. Pascucci, M. Musti, C. Nicita, P. Barbieri, A. Marinaccio, C. Magnani, D. Mirabelli
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A median survival time of about 9 months is generally reported among malignant pleural mesothelioma cases. Recently, better results in terms of survival and performance status have been reported in clinical trials that included highly selected patients. We describe the survival of pleural mesothelioma patients and the factors predictive of survival in an unselected, population‐based setting. Pleural mesothelioma cases (4,100) registered from 1990 to 2001 by 9 Italian regional mesothelioma registries contributing to the network of the National Mesothelioma Registry were followed until December 31, 2005. Univariate (Kaplan‐Meier) and multivariate (Cox proportional hazards regression) analyses of survival were carried out according to selected individual characteristics, including limited information on treatment in a subset of 578 cases. The median survival time was 9.8 months (95% confidence interval: 9.4–10.1). In multivariate analysis, younger age at diagnosis and epithelioid histotype were associated with significantly reduced hazard ratios. Positive effects of gender (women) and being diagnosed in a hospital with a thoracic surgery unit were of border‐line statistical significance. No association with calendar period of diagnosis or asbestos exposure was present. Treatment was not associated with a statistically significant improvement in survival. This is the largest population‐based study on survival in patients with pleural mesothelioma to date. Age and morphology were the main prognostic factors. Results regarding the effect of treatment were disappointing but may be useful to assess the future impact, at the population level, of recently introduced therapies. © 2008 Wiley‐Liss, Inc.
This paper references
10.1016/J.EJCA.2007.09.018
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
A. Marinaccio (2007)
ruolo dell’esposizione lavorativa ed ambientale ad amianto nella genesi dei casi di mesotelioma insorti in residenti del Veneto
E Merler (2006)
10.1007/S004200100240
Malignant mesothelioma – German mesothelioma register 1987–1999
V. Neumann (2001)
10.1177/030089160208800403
Survival after Pleural Malignant Mesothelioma a Population-based Study in Italy
C. Magnani (2002)
Gazzetta Ufficiale della Repubblica Italiana numero 200 (supplemento ordinario)
(1991)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1023/A:1026300619747
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends
F. Montanaro (2004)
10.1093/ANNONC/MDL060
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
R. Hassan (2006)
Regional Operational Centers
M Nesti (1997)
Incidence and survival of mesothelioma in Osaka
N Kanazawa (2006)
Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali. seconda edizione
It Istituto Superiore di Sanit (2004)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
10.1002/AJIM.10313
Malignant mesothelioma in Italy, 1997.
M. Nesti (2004)
10.1016/S0959-8049(03)00233-8
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
10.1136/oem.52.11.775
Differences in occupational mortality from pleural cancer, peritoneal cancer, and asbestosis.
D. Coggon (1995)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
Standards and Guidelines for Cancer Registration in Europe. The ENCR Recommendationts
D Pheby (2003)
10.1097/00008469-199908000-00007
Increased but low incidence and poor survival of malignant mesothelioma in the southeastern part of The Netherlands since 1970: a population-based study.
M. Janssen-Heijnen (1999)
Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all’ISPESL da parte dei centri operativi regionali
A Moccaldi (2003)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
Regional Operational Centers. Malignant mesothelioma in Italy, 1997
M Nesti (2004)
10.1093/ANNONC/MDL345
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
lignant mesothelioma in Italy , 1997
M Nesti (2005)
Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience.
M. Nesti (2005)
10.1093/ANNHYG/44.8.565
The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.
J. Hodgson (2000)
[Survival analysis of malignant mesothelioma treated in Brescia, northern Italy, 1982-2000].
P. Barbieri (2004)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1093/JJCO/HYL018
Incidence and survival of mesothelioma in Osaka, Japan.
Naoko Kanazawa (2006)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1038/sj.bjc.6602240
Cancer mortality in a cohort of asbestos textile workers
E. Pira (2005)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1097/00008469-200506000-00001
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study
G. Gorini (2005)
Incidence date
D Pheby (2007)
[Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
N. Desoubeaux (2001)
Standards and Guidelines for Cancer Registration in Europe
D Pheby (2003)
10.1002/ijc.23866
Survival of peritoneal malignant mesothelioma in Italy: A population‐based study
D. Mirabelli (2009)
10.1002/ijc.20820
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
10.1093/ANNONC/MDL428
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
T. Yan (2007)
Il ruolo dell'esposizione lavorativa ed ambientale ad amianto nella genesi dei casi di mesotelioma insorti in residenti del Veneto
E Merler (2006)
Population-based epidemiology and prognosis of mesothelioma in Leeds, United Kingdom
A Chapman (2008)
10.1136/oem.2007.032847
Cancer risk after cessation of asbestos exposure: a cohort study of Italian asbestos cement workers
C. Magnani (2007)



This paper is referenced by
10.1183/09031936.00000811
Predicting survival in malignant mesothelioma
A. Musk (2011)
10.5301/tj.5000418
Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma
R. Berardi (2016)
10.1967/s002449910904
18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
A. Niccoli Asabella (2018)
Clinicopathologic and Survival Characteristics of Malignant Pleural Mesothelioma Registered in Hospital Cancer Registry
Kosar Najmi (2014)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1111/crj.12383
Malignant mesothelioma with fungating masses and multiple sites involvement
J. K. Sim (2017)
10.3892/ijo.2016.3358
Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma.
V. Amatya (2016)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.1002/ajim.22716
Pleural malignant mesothelioma in dental laboratory technicians: A case series
C. Mensi (2017)
10.5798/DICLEMEDJ.0921.2013.02.0262
Malign Plevral Mezotelyoma prognozunda yeni bir inflamatuar parametrenin değeri
Çetin Tanrıkulu (2013)
10.1136/oem.2009.051466
Incidence of extrapleural malignant mesothelioma and asbestos exposure, from the Italian national register
A. Marinaccio (2010)
10.1016/j.jtcvs.2012.09.023
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.
M. Baud (2013)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.1007/978-88-470-5711-1_2
Epidemiology: Extent of the Problem
Simone Sibio (2015)
10.1016/j.lungcan.2018.05.018
Assessing the completeness and correctness of the registration of malignant mesothelioma in Belgium.
Michael Rosskamp (2018)
10.1177/172460080902400208
Osteopontin is not a Specific Marker in Malignant Pleural Mesothelioma
Laura Paleari (2009)
10.4103/0970-2113.85688
Clinical characteristics and treatment outcomes in 132 patients with malignant mesothelioma
A. Abakay (2011)
10.5114/aoms.2010.19303
Epidemiology of mesothelioma in Egypt. A ten-year (1998-2007) multicentre study
Yosri M. Akl (2010)
10.3346/jkms.2017.32.11.1879
A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
J. Kim (2017)
10.6004/JNCCN.2012.0181
Photodynamic therapy for malignant pleural mesothelioma.
Joseph S. Friedberg (2012)
10.1007/s00280-010-1314-0
In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects
I. Zanellato (2010)
UWA Research Publication
Emma Kowal (2013)
Almost half of women with malignant mesothelioma were exposed to asbestos at home through their husbands or sons.
M. Langhoff (2014)
10.1177/030089161209800206
Effects of Combined Therapies on the Survival of Pleural Mesothelioma Patients Treated in Brescia, 1982–2006
Pietro Gino Barbieri (2012)
10.5772/55722
Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies
K. Lau (2013)
Effects of treatment regimens on survival in patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.1007/s13665-013-0045-1
Prognostic factors for malignant pleural mesothelioma
F. Brims (2013)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.3390/ijerph14111379
Asbestos Ban in Italy: A Major Milestone, Not the Final Cut
Daniela Marsili (2017)
Use of artificial intelligence techniques for diagnosis of malignant pleural mesothelioma Malign plevral mezotelyoma tanısı için yapay zeka teknikleri kullanımı
Orhan Er (2015)
10.1002/cncr.26497
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
Caratterizzazione della risposta immunitaria in biopsie pleuriche di pazienti affetti da mesotelioma epiteliale e sarcomatoso
L. Lasagna (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar